Episode 27 - Integrating Quadruplet Regimens in Newly Diagnosed Multiple Myeloma: Patient Focused Strategies to Improve Outcomes - Part 3: Treatment of Frail Patients With NDMM and Key Emerging Trials

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).

Launch Date: July 19, 2024

Release Date: June 26, 2024

Expiration Date: June 30, 2025

FACULTY

Robert Orlowski, MD, PhD

Professor of Medicine

Director, Section of Myeloma

The University of Texas, MD Anderson Cancer Center

Noopur Raje, MD

Director, Center for Multiple Myeloma

Massachusetts General Hospital

Peter Voorhees, MD

Chief, Plasma Cell Disorders Division

Atrium Health / Levine Cancer Institute

Clinical Professor of Medicine

Wake Forest University School of Medicine

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43